Valuation: Alvotech

Market Cap 1.8B 1.6B 1.48B 1.34B 2.52B 170B 2.56B 17.77B 6.98B 89B 6.73B 6.59B 284B P/E 2026 *
120x
P/E 2027 * 16.8x
Enterprise Value 2.87B 2.56B 2.37B 2.15B 4.03B 272B 4.1B 28.42B 11.16B 142B 10.77B 10.55B 454B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 3.63x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.60%
1 week-8.55%
Current month-13.28%
1 month-14.31%
3 months+45.38%
6 months+39.34%
Current year-1.95%
1 week 4.95
Extreme 4.95
5.51
1 month 4.95
Extreme 4.95
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.53
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 57 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Free

Chief Executive Officer

117,271 0.0355%
4/1/26 Sell

Founder

318,000 0.0963%
4/1/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%-8.55%-42.32%-43.16% 1.8B
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +2.86%-0.19%+42.90%+106.37% 37.76B
Weighted average by Cap. +3.05%+0.58%+50.68%+123.65%

Financials

2026 *2027 *
Net sales 653M 581M 538M 488M 917M 61.83B 932M 6.46B 2.54B 32.36B 2.45B 2.4B 103B 786M 700M 648M 587M 1.1B 74.45B 1.12B 7.78B 3.06B 38.96B 2.95B 2.89B 124B
Net income 2.25M 2M 1.85M 1.68M 3.16M 213M 3.21M 22.23M 8.73M 111M 8.43M 8.25M 355M 80.1M 71.29M 66.08M 59.88M 113M 7.59B 114M 793M 311M 3.97B 300M 294M 12.67B
Net Debt 1.08B 957M 887M 804M 1.51B 102B 1.54B 10.65B 4.18B 53.32B 4.03B 3.95B 170B 1.06B 940M 871M 789M 1.48B 100B 1.51B 10.45B 4.11B 52.35B 3.96B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-10-18 US$5.030 +0.60% 907,729
26-10-16 US$5.000 -5.84% 1,059,087
26-10-15 US$5.310 +2.71% 1,156,272
26-10-14 US$5.170 -3.90% 1,058,173
26-10-13 US$5.380 -2.18% 1,214,031
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.030USD
Average target price
7.200USD
Spread / Average Target
+43.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock